Alloy Therapeutics is led by a team that has put hundreds of antibodies into the clinic and has the ability to address the unique challenges with novel and innovative solutions.
Chief Strategy Advisor
Strategy scholar and professor at Dartmouth’s Tuck School of Business. Leading expert on ecosystem strategy and author of The Wide Lens: What Successful Innovators See that Others Miss and Winning the Right Game: How to Disrupt, Defend, and Deliver in a Changing World.
Founder, CEO, Chairman of Alloy
Bioengineer, entrepreneur, and investor who has founded or co-founded several venture-backed biotech companies, including Adimab, Alloy Therapeutics, Compass Therapeutics, Alector, Arsanis, and Avitide.
President of Alloy
Translational scientist with more than 25 years of hands-on research experience. Co-inventor of more than 40 patent families. Contributed to and led scientific efforts at Compass Therapeutics, Adimab, Merck and GlycoFi, delivering novel drug discovery platforms and clinical programs.
SVP, Drug Development
Head of Gx Business Unit, Senior Counsel
Fluent in science, business, and law, Patrick’s mission is to make robust transgenic animal models available across the drug discovery ecosystem. He drafts and negotiates collaboration and license agreements involving intellectual property, and liaises with Alloy’s partners as they advance drug candidates toward market authorization.
Head of Legal
Lead counsel & registered patent attorney with 15 years of practice experience in the field of biotechnology research, development, and commercialization. Previously represented large institutions across the Commonwealth of Massachusetts in counsel and business development roles, as well as practiced patent prosecution.
Associate Director, UK Operations and Co-head Alloy UK
CBO, Genetic Medicines and Head of Corporate Development
Biotech and Pharma industry veteran with 30+ years of experience in licensing, corporate strategy, and M&A. Held key roles at leading companies: Intellia, Metagenomi, Acceleron, Teva, GSK, and Wyeth.
Senior Director, Machine learning & Data engineering and Co-head Alloy Basel
Scientist and entrepreneur with deep expertise in computational biology and protein engineering. Passionate about building cross-functional teams to deliver cutting-edge solutions for drug discovery. Prior to joining Alloy Therapeutics, Simon co-founded deepCDR Biologics.
Senior Director, Head of People
People & Talent leader with expertise in building teams and scalable people infrastructure. Previously led the People function at Blank Street and built and scaled teams at Astra.
SVP, Therapeutic Discovery Strategies
25 years experience in discovering therapeutic antibodies supporting a variety of drug modalities and clinical indications.
Senior Director, Head of Genetically Engineered Organisms and Co-head Alloy UK
CSO, Alloy
CBO, Head of Antibodies and
Strategic Collaborations
An operator with over 20 years of experience in biotech company formation, operations, alliance management, and business development – Heather enjoys building new things and driving them to profitability. Previous roles were with Verseau Therapeutics, Harbour Antibodies and Atlas Venture.
CEO of Daedamab and Head of Alloy Athens
Head of Cell Therapies and Head of Alloy Japan
Experienced biotech executive with track record in biotech investments, platform builds and regional ecosystem development. Major platform builds include Takeda-Kyoto University iPS CAR-T platform (now Alloy Cell Therapies) and largest SMOL platform in Japan (now full-service CRO Axcelead).
CFO, Alloy
Head of Sovereign Innovation Business Unit
Alasdair is a life science focussed entrepreneur and investor. He has been a Venture Capital investor at Index Ventures, Medicxi, Leaps by Bayer (Bayer AG), Ada Ventures and Mubadala Capital investing in drug development/healthcare projects. He is a co-founder at Multiomic Health and Selvedge Venture (Solo GP seed fund). Prior to joining Alloy he additionally supported BD&L and Acquisitions at the Ellison Institute of Technology, Oxford. Alasdair holds degrees from the University of Cambridge (MPhil) and SOAS, University of London (BA, Hons).
CSO, Genetic Medicines
Senior Director, Data Science & Bioinformatics and Co-head Alloy Basel
CEO of Keyway TCR Discovery
CFO, Alloy
Senior Director, Data Science & Bioinformatics and Co-head Alloy Basel
Senior Director, Data Science & Bioinformatics and Co-head Alloy Basel
Ecosystem
Company
Insights
© 2025 Alloy Therapeutics, Inc. All Rights Reserved.
